Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of advanced renal cell carcinoma (RCC), yet only a subset of patients derives durable clinical benefit and no robust predictive biomarkers have been implemented in routine clinical practice. As T-cell receptor (TCR)-mediated antigen recognition underlies effective antitumor immunity, characterization of the intratumoral TCR repertoire may provide clinically relevant information for patient stratification. Here, we evaluated the predictive value of the baseline intratumoral TCR{beta} and TCR{gamma} repertoires in a rea
Baseline intratumoral TCRbeta; and TCRgamma; repertoires predict response to immune checkpoint inhibitors in advanced renal cell carcinoma
calendar_today
September 6, 2026
person
Pino Gonzalez, M., Lazaro Quintela, M. E., Oria de Rueda, G. d. V., Duenas Porto, M., Alonso Alvarez, I., Francisco Fernandez, A., San Miguel Fraile, M. P., Ortiz Rey, J. A., Gallardo Gomez, M., Carracedo Videira, L., Gallach Garcia, S., Jantus Lewintre, E., Martinez Fernandez, M.
domain
medrxiv